Aprea Therapeutics, Inc. (APRE)
Aprea Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Boston, PA, US. The stock last traded at $0.67, up 2.24% on the session, giving a market capitalisation of $8.4M. On trailing twelve-month figures it carries a trailing P/E of -0.52, a net margin of 0.0%. Its beta of 1.59 implies it has historically moved more than the broad market.
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Aprea Therapeutics, Inc. is most often compared with the following Healthcare names: